Get notified when RNTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report includes a going-concern warning, indicating the company may not be able to continue operating.
- Floor Price (new) — The agreement includes a floor price of $0.28 per share, which may limit downside protection for the company if the stock price falls significantly.
Rein Therapeutics to raise up to $6M via Yorkville Pre-Paid Advance at $1.41/share
Filed July 30, 2025 · ~1 min read
Key Changes
-
high
Rein Therapeutics is offering up to $6M of common stock to Yorkville under a Pre-Paid Advance Agreement, with shares issued at a discount to market.
The Offering verify on EDGAR → -
high
The company will initially receive $1M in net proceeds, with an additional $5M available at Yorkville's sole discretion.
Use of Proceeds verify on EDGAR → -
high
New investors pay $1.41/share but get $0.44/share pro forma net tangible book value, an immediate dilution of $0.97/share.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (IMMR 10-Q) is open in full — no account needed.
Partner
Trade RNTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 3, 2026 · How we verify